Security key
74587V107
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)
CUSIP: 74587V107
Q2 2017 13F Holders as of 30 Jun 2017
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 35,525,549
- Total 13F value
- $3,104,620,640
- Share change
- -259,843
- Put/Call ratio
- 102%
- SEC-reported price per share
- $87.40
- Number of holders
- 152
- Value change
- +$57,539,772
- Number of buys
- 92
- Number of sells
- 73
- Shares outstanding
- 49,633,071
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2017
Institutions
152
Top holders
10
PBYI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2017
Previous quarter: Q1 2017
PUMA BIOTECHNOLOGY, INC. SEC filings
PUMA BIOTECHNOLOGY, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74587V107
Recent filing periods:
Ownership snapshot
Top reported holders of PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ADAGE CAPITAL PARTNERS GP...
Disclosed value leader
ADAGE CAPITAL PARTNERS GP...
Comparable rows
15/15
Latest evidence
31 Mar 2017
13F
Lead comparable stake: 11%
Showing 1-6 of 15 holder rows.
Quick read
ADAGE CAPITAL PARTNERS GP, L.L.C. leads the comparable SEC ownership view at 11%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ADAGE CAPITAL PARTNERS GP, L.L.C.'s linked filing trail.
Comparable ownership
Top 5
ADAGE CAPITAL PARTNERS GP, L.L.C.
11%
FMR LLC
7.1%
WELLINGTON MANAGEMENT GROUP LLP
5.1%
VANGUARD GROUP INC
4.9%
ORBIMED ADVISORS LLC
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
11%
|
$211,544,000
5,686,668 shares
|
— | 31 Mar 2017 |
| FMR LLC |
13F
Company
|
7.1%
|
$131,715,000
3,540,729 shares
|
— | 31 Mar 2017 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
5.1%
|
$94,464,000
2,539,350 shares
|
— | 31 Mar 2017 |
| VANGUARD GROUP INC |
13F
Company
|
4.9%
|
$90,355,000
2,428,909 shares
|
— | 31 Mar 2017 |
| ORBIMED ADVISORS LLC |
13F
Company
|
4.5%
|
$83,548,000
2,245,925 shares
|
— | 31 Mar 2017 |
| JANUS HENDERSON INVESTORS US LLC |
13F
Company
|
4.5%
|
$82,195,000
2,209,599 shares
|
— | 31 Mar 2017 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2017
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
152
Shares
35,525,549
Rows available
152
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2017 vs Q1 2017 Across Filers
Q1 2017 holders
135
Q2 2017 holders
152
Holder diff
17
| Investor | Q1 2017 Shares | Q2 2017 Shares | Share Diff | Share Chg % | Q1 2017 value | Q2 2017 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend